Arnob Banerjee
35 Papers
Arnob Banerjee is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 11 publications.
Chat about Author
Papers
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Yi Lin,Thomas R. Martin,Saad Usmani,Jesus G. Berdeja,Andrzej Jakubowiak,Mounzer E. Agha,Adam E. Cohen,Abhinav Deol,Myo Htut,Alexander M. Lesokhin,Nikhil C. Munshi,Elizabeth O'Donnell,Carolyn C. Jackson,Tzu-min Yeh,Arnob Banerjee,Enrique Zudaire,Deepu Madduri,Lida Bubuteishvili-Pacaud,Sundar Jagannath +18 more
TL;DR: In this paper , a single infusion of ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy targeting BCMA, was shown to increase the median overall survival (OS) of patients with relapsed/refractory multiple myeloma.
65
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Yael C Cohen,Daniel Morillo,Moshe E. Gatt,Michael Sebag,Ki-Hyun Kim,Chang-Ki Min,Albert Oriol,Enrique M. Ocio,Sung-Soo Yoon,Maria-Victoria Mateos,Michael Chu,Paula Rodriguez-Otero,Irit Avivi,Yue Guo,Maria Krevvata,Melissa Beelen,Jill M. Vanak,Arnob Banerjee,Hila Magen +18 more
TL;DR: The first results from the phase 1b RedirecTT-1 trial (NCT04586426) in pts with RRMM were reported in this paper , where the first combination study of a BCMA-and GPRC5D-targeted bispecific antibody, tec + tal, was presented.
50
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
Simon J. Harrison,Tamia Nguyen,Marzia Rahman,Jeremy Er,Jessica Li,Katherine Li,N. Lendvai,Jordan M. Schecter,Arnob Banerjee,Tito Roccia,Brad Foulk,Junchen Gu,Hao Zhao,Denis Smirnov,A. Slaughter,Carolina Lonardi,Erin Lee,Loreta Marquez,Shirin Jadidi,Octavio Costa Filho,Nitin Patel,Dong Geng,Nicole M Haynes,Hannah Kelly,Stephen Lade,Sean M. Grimmond,Piers Blombery +26 more
TL;DR: The clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ TCL post cilta-cel is presented, suggesting tumor monoclonality.
47
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
Thomas R. Martin,Maria-Victoria Mateos,Ajay K. Nooka,Arnob Banerjee,Rachel Kobos,Lixia Pei,Ming Qi,Raluca I. Verona,Margaret Doyle,Jennifer Smit,Weili Sun,D. Trancucci,Clarissa M. Uhlar,N. W. C. J. van de Donk,C A Rodríguez +14 more
TL;DR: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, demonstrated an overall response rate of 63.0% in 165 heavily pretreated patients with relapsed or refractory multiple myeloma in the phase 1/2 MajesTEC•1 study as mentioned in this paper .
27
Teclistamab impairs humoral immunity in heavily pretreated MM patients: importance of immunoglobulin supplementation.
Kristine A. Frerichs,Christie P. M. Verkleij,MV Mateos,Thomas G Martin,Ajay K Nooka,Arnob Banerjee,K. Chastain,Alfredo Perales Puchalt,Tara Stephenson,Clarissa M. Uhlar,Rachel Kobos,Bronno R Van Der Holt,Sandy Kruyswijk,Maria T. Kuipers,Kaz Groen,Deeksha Vishwamitra,Sheri Skerget,Diana Cortes-Selva,Margaret Doyle,Hans L Zaaijer,S. Zweegman,Raluca I. Verona,N. W. van de Donk +22 more
TL;DR: IVIG use was associated with a significantly lower risk of serious infections among patients receiving teclistamab treatment and teclistamab induces severe defects in humoral immunity with decreased polyclonal immunoglobulin levels and impaired vaccination responses.
21